Document Detail


Transdermal delivery of nitric oxide from diazeniumdiolates.
MedLine Citation:
PMID:  9685912     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Adverse physiological effects can often interfere with the use of nitric oxide (NO) as a therapeutic agent, especially when it is systemically generated from prodrugs. NO which is generated and delivered site-specifically by transdermal donors may be useful in the treatment of parasitic, bacterial or viral skin infections without causing systemic side effects. Three diazeniumdiolates (formerly "NONOate"), including two water soluble compounds, (Z)-1-[N-2-aminoethyl)-N-(2-ammonioethyl)amino]-diazen-1- ium-1,2-diolate (DETA-NO) and (Z)-1-[N-(3-aminopropyl)-N-(3-ammoniopropyl)amino] diazen-1-ium-1,2-diolate (DPTA-NO), and one insoluble compound, DPTA-NO grafted to dextran microspheres (DPTA-NO-g-dextran) were used to transdermally deliver NO to rats. Dextran microspheres were obtained by simultaneously grafting DPTA-NO to dextran and cross-linking dextran with CNBr in an oil-water emulsion. Suspended in hydrogel, DETA-NO, DPTA-NO, and DPTA-NO-g-dextran were applied three times to depilated rats at 4 day intervals. Results show that metabolic urinary nitrate levels increase with time (24-48 h), reach a maximum, and return to baseline by the fourth day. DPTA-NO applications produced an average maximum nitrate level of 94.2 mumol/day +/- 34.2 mumol S.D. compared to the average maximum nitrate level of 39.8 mumol/day +/- 8.6 mumol S.D. obtained from treatment with DETA-NO. These results suggest that DPTA-NO delivered NO more efficiently than DETA-NO. When DPTA-NO-g-dextran microspheres were used as the NO donor, results comparable to DPTA-NO were observed with an average maximum nitrate level of 14.9 mumol/day +/- 3.0 mumol S.D. These and other conclusive data indicate that, via these diazeniumdiolates, NO can be delivered effectively through rat skin.
Authors:
D J Smith; M L Simmons
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of controlled release : official journal of the Controlled Release Society     Volume:  51     ISSN:  0168-3659     ISO Abbreviation:  J Control Release     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-09-21     Completed Date:  1998-09-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8607908     Medline TA:  J Control Release     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  153-9     Citation Subset:  IM    
Affiliation:
Department of Chemistry, University of Akron, OH 44325-3601, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Animals
Azetidines / administration & dosage,  metabolism*
Cross-Linking Reagents / chemistry
Cyanogen Bromide / chemistry
Dextrans / administration & dosage,  chemistry,  metabolism*
Male
Microspheres
Nitrates / urine
Nitric Oxide / administration & dosage*,  urine
Prodrugs / administration & dosage*
Rats
Rats, Sprague-Dawley
Triazenes / administration & dosage*
Chemical
Reg. No./Substance:
0/1-(N-(3-aminopropyl)-N-(3-ammoniopropyl)amino)diazen-1-ium-1,2-diolate-dextran; 0/1-(N-(3-ammoniopropyl)-N-(n-propyl)amino)diazen-1-ium-1,2-diolate; 0/1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene; 0/Azetidines; 0/Cross-Linking Reagents; 0/Nitrates; 0/Prodrugs; 0/Triazenes; 10102-43-9/Nitric Oxide; 506-68-3/Cyanogen Bromide; 9004-54-0/Dextrans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect...
Next Document:  Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer.